Vivos Therapeutics (VVOS) Non-Current Debt (2020 - 2026)

Vivos Therapeutics' (VVOS) quarterly Non-Current Debt came in at $418000.0 in Q1 2026, down 10.87% on a QoQ basis from $469000.0 in Q4 2025.

Vivos Therapeutics (VVOS) Non-Current Debt (2020 - 2026) Analysis & Trends

Vivos Therapeutics (VVOS) has 4 years of Non-Current Debt data on file, last reported at $418000.0 in Q1 2026.

On a quarterly basis, Non-Current Debt changed N/A year-over-year to $418000.0 in Q1 2026; TTM through Mar 2026 was $418000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $469000.0, changed N/A from the prior year.
Non-Current Debt for Q1 2026 stood at $418000.0, down from $469000.0 in the prior quarter.
Over the last five years, Non-Current Debt for VVOS reached as high as $8.4 million in Q3 2025 and fell as low as $418000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	29.64 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	14.22 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	26.17 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	10.99 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	598.50 Mn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	8.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	10.13 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	3.18 Bn
10	Vivos Therapeutics	3.62 Mn	1.38 Mn	3.06 Mn	418,000.00

Download Data